0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF R2

VEGF R2

Brief Information

Name:Vascular endothelial growth factor receptor 2
Target Synonym:EC:2.7.10.1,EC 2.7.10,VEGFR2,KDR,Vascular endothelial growth factor receptor 2,Fetal liver kinase 1,Kinase insert domain receptor,Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase),Protein-Tyrosine Kinase Receptor Flk-1,FLK1,Tyrosine Kina
Number of Launched Drugs:14
Number of Drugs in Clinical Trials:41
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

KDR-H82E5-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

KDR-H82E5-ELISA
Biotinylated Human VEGF R2, Avitag,His TagBiotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) ELISA bioactivity

Immobilized ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a linear range of 10-156 ng/mL (QC tested).

Synonym Name

KDR,CD309,FLK1,VEGFR,VEGFR2

Background

Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and  is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Midostaurin PKC-412; PKC-412A; CGP-41231; CGP-41251 Approved Novartis Pharma Ag Rydapt EU Leukemia, Myeloid, Acute; Mastocytosis Novartis Europharm Ltd 2017-04-28 Hematologic Neoplasms; Leukemia; Mastocytosis, Systemic; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis Details
Tivozanib AV-951; KRN-951; ASP-4130; Kil-8951 Approved Kyowa Hakko Kirin Co Ltd Fotivda United States Carcinoma, Renal Cell Aveo Pharmaceuticals Inc 2017-08-24 Solid tumours; Carcinoma, Renal Cell; Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc 多吉美, Nexavar EU Thyroid Neoplasms Bayer Ag 2005-12-01 Liver Diseases; Neoplasm Metastasis; Fasting; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Thyroid Neoplasms; Hepatitis C; Hepatitis B; Breast Neoplasms; Liver Neoplasms; Neoplasms; Pancreatic Neoplasms; Kidney Diseases; Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Solid tumours; Ovarian Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive Details
Pazopanib Hydrochloride GW-786034; SB-786034; GSK-786034; GW-786034B Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Patorma, Votrient Mainland China Carcinoma, Renal Cell Novartis Pharma Schweiz Ag 2009-10-19 Osteosarcoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Sarcoma; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hemangiosarcoma; Carcinoma, Renal Cell; Solid tumours; Chondrosarcoma; Telangiectasia, Hereditary Hemorrhagic Details
Fruquintinib HMPL-013 Approved Hutchison Medipharma Ltd 爱优特, Elunate Mainland China Colorectal Neoplasms Hutchison Huangpu Medicine (Shanghai) Co Ltd 2018-09-04 Solid tumours; Rectal Neoplasms; Esophageal Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Regorafenib Monohydrate BAY-73-4506; DAST Approved Bayer Ag Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Axitinib AG-013736; PF-01367866; AG-13736 Approved Pfizer Pharmaceuticals Ltd (China) 英立达, Inlyta Mainland China Carcinoma, Renal Cell Pfizer Europe Ma Eeig 2012-01-27 Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Skin Neoplasms; Myelodysplastic Syndromes; Endometriosis; Hepatic Insufficiency; Thyroid Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Macular Degeneration Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Small Cell Lung Carcinoma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Sarcoma, Alveolar Soft Part; Cholangiocarcinoma; Lung Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Osteoma; Triple Negative Breast Neoplasms; Solid tumours; Ovarian Neoplasms; Leiomyosarcoma; Liver Neoplasms; Genital Diseases, Female; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Sarcoma, Synovial; Neuroendocrine Tumors; Medullary thyroid cancer (MTC); Sarcoma Details
Apatinib Mesylate YN-968D1 Approved Advenchen Laboratories 艾坦, Aitan Mainland China Stomach Neoplasms Jiangsu shengdi Medicine Co Ltd 2014-10-17 Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef Mainland China Idiopathic Pulmonary Fibrosis Boehringer Ingelheim International Gmbh 2014-10-15 Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Surufatinib HMPL-012 Approved Hutchison Medipharma Ltd 苏泰达, SULANDA Mainland China Neuroendocrine Tumors Hutchison Huangpu Medicine (Shanghai) Co Ltd 2020-12-29 Biliary Tract Neoplasms; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Kidney Diseases; Neuroendocrine Tumors; Bile Duct Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine Details
Ramucirumab IMC-1121; IMC-1C11; BLA-125477; IMC-1121-B; LY-3009806 Approved Dyax Pharma Cyramza United States Carcinoma, Hepatocellular Eli Lilly And Co Ltd 2014-04-21 Breast Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Ureteral Neoplasms; Peritoneal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Urethral Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Solid tumours; Urinary Bladder Neoplasms; Microsatellite instability-high cancer; Colonic Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Skin Melanoma; Biliary Tract Neoplasms Details
Lenvatinib Mesylate ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 United States Endometrial Neoplasms Eisai Inc 2015-02-13 Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gallbladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Sarcoma; Liver Diseases; Liver Neoplasms; Triple Negative Breast Neoplasms; Kidney Diseases; Small Cell Lung Carcinoma; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Esophageal Neoplasms; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours Details
Cabozantinib S-malate BMS-907351; XL-184 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Solid tumours; Pain; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD Approved Pfizer Pharmaceuticals Ltd (China) Sutent, 索坦 Japan Pancreatic neuroendocrine tumors (pNET) Pfizer Inc 2006-01-26 Diabetic macular oedema; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Retinal Vein Occlusion; Carcinoma, Hepatocellular; Urogenital Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Prostatic Neoplasms; Breast Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Urologic Diseases; Kidney Diseases; Pancreatic neuroendocrine tumors (pNET); Pancreatic Neoplasms; Carcinoma, Islet Cell; Stomach Neoplasms; Carcinoma, Renal Cell; Solid tumours; Liver Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No.4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms Details
VEGFR-1/2 peptide vaccine (Keio University) Phase 2 Clinical Keio University Neurofibromatoses; Brain Neoplasms; Glioma Details
VEGFR2 peptide vaccine (Tokyo University) Phase 1 Clinical University Of Tokyo Pancreatic Neoplasms Details
Glesatinib MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly Phase 2 Clinical Mirati Therapeutics Carcinoma, Non-Small-Cell Lung Details
VEGFR2 peptide vaccine (VAXIMM) VXM-01 Phase 2 Clinical Merck Serono Pancreatic Neoplasms; Glioblastoma; Colorectal Neoplasms; Glioma Details
AVI-3207 AVI-3207 Phase 1 Clinical Avixgen Macular Degeneration Details
Hydroxychloroquine/Sorafenib Phase 1 Clinical Vg Life Sciences Ovarian Neoplasms Details
Orantinib TSU-68; SU-6668; SU-006668 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Liver Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular Details
LMV-12(HE003) LMV-12(HE003) Phase 1 Clinical Nanchang Hongyi Technology Co Ltd Solid tumours Details
Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) Phase 1 Clinical Sichuan Kelun Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Telatinib EOC-315; BAY-57-9352 Phase 2 Clinical Bayer Ag Solid tumours; Stomach Neoplasms Details
Ramucirumab biosimilar (CTTQ) Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant human anti-VEGFR2 monoclonal antibody (Buchang Pharma) BC-001 Phase 1 Clinical Shandong Buchang Pharmaceuticals Co Ltd Solid tumours Details
Tafetinib Malate SIM-0702; SIM-1005; SIM-010603 Phase 1 Clinical Jiangsu Xiansheng Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
MSB-0254 MSB-0254 Phase 1 Clinical Mabspace Biosciences Solid tumours Details
Metatinib Trometamol BMS-817378; SIM-817378 Phase 1 Clinical Bristol-Myers Squibb Company Liver Neoplasms; Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
HLX-12 HLX-12 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Kanitinib CX-1003 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Esa Biotech Solid tumours; Esophageal Neoplasms; Prostatic Neoplasms Details
SOMCL-15-290 SOMCL-15-290 Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Squamous Cell Details
Recombinant anti-VEGFR2 chimeric monoclonaly antibody (GeneScience) Phase 2 Clinical Changchun Genescience Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Sorafenib/MG-005 MGD-1509 Phase 1 Clinical Metagone Biotech, Tri-Service General Hospital Solid tumours Details
BR-55 BR-55 Phase 2 Clinical Sonus Pharmaceuticals Ovarian Neoplasms; Prostatic Neoplasms Details
Dovitinib TKI-258; CHIR-258; GFKI-258; CHIR-258LC; NVP-TKI258 Phase 2 Clinical Novartis Pharma Ag Carcinoma, Adenoid Cystic; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Prostatic Neoplasms; Breast Neoplasms; Solid tumours; Adrenocortical Carcinoma; Multiple Myeloma; Pancreatic Neoplasms; Glioblastoma; Adenocarcinoma, Scirrhous; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Liver Neoplasms; Linitis Plastica; Stomach Diseases Details
PAN-90806 CP-632; OSI-632; CP-547632; PAN-90806 Phase 2 Clinical Pfizer Inc, Osi Pharmaceutical Ovarian Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Diabetic Retinopathy; Macular Degeneration Details
Cediranib AZD2171; AZD-2171; NSC-732208 Phase 2 Clinical Astrazeneca Plc Glioblastoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Biliary Tract Neoplasms; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Liver Neoplasms; Leukemia; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms Details
Brivanib Alaninate ZL-2301; BMS-540215; BMS-582664 Phase 3 Clinical Bristol-Myers Squibb Company Solid tumours; Liver Neoplasms; Rectal Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Sarcoma; Colorectal Neoplasms; Gastrointestinal Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
AK-109 AK-109 Phase 2 Clinical Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma Details
CEP-11981 ESK-981; CEP-11981; SSR-106462; BOL-303213X Phase 2 Clinical Sanofi Prostatic Neoplasms Details
Altiratinib DP-5164; DCC-2701; DCC-22701; T-678746713 Phase 1 Clinical Deciphera Solid tumours; Neoplasms Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
AXT-107 AXT-107 Phase 2 Clinical AsclepiX Therapeutics Inc Diabetic macular oedema; Macular Degeneration Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Stomach Neoplasms Details
TAS-115 TAS-115 Phase 1 Clinical Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd Neoplasms Details
JY-025 JY-025 Phase 3 Clinical Beijing Jingyi Taixiang Technical Development Co Ltd, Beijing Eastern Biotech Co Ltd Solid tumours; Liver Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Olinvacimab SSS-23; TTAC-0001 Phase 2 Clinical Pharmabcine Glioblastoma; Triple Negative Breast Neoplasms; Neoplasm Metastasis Details
Ningetinib Tosylate CT-053; CT-053-PTSA Phase 2 Clinical Hec Pharm Co Ltd Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Sitravatinib MG-516; MG-91516; MGCD-516; IND-155305 Phase 3 Clinical Mirati Therapeutics Solid tumours; Carcinoma; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Hepatic Insufficiency; Ureteral Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular Details
Chiauranib CS-2164 Phase 3 Clinical Shenzhen Chipscreen Biosciences Co Ltd Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop